ArticleJournal of medical case reports2025
Recurrent giant retroperitoneal dedifferentiated liposarcoma requiring challenging multiorgan resection: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDedifferentiated liposarcoma is a rare, aggressive subtype of liposarcoma known for its high recurrence rate and local invasiveness. This case demonstrates the challenges in managing a rapidly recurring dedifferentiated liposarcoma and underscores the need for improved surveillance and additional treatment options. CASE PRESENTATION: A 57-year-old non-Hispanic white male presented in November 2023 with a 2-month history of intermittent fevers, nonproductive cough, and lower abdominal discomfort. Imaging revealed a 12 cm × 12 cm × 16 cm retroperitoneal mass, confirmed to be a high-grade dedifferentiated liposarcoma. Initial surgical resection in December 2023 removed the tumor, which was densely adhered to the left kidney. Despite adjuvant chemotherapy, follow-up imaging in July 2024 showed tumor recurrence with a 15 cm × 14 cm × 21 cm multiloculated cystic mass extending from the spleen to the lower pole of the kidney, as well as a 12 cm × 6 cm × 15 cm mass inferior to the left kidney. Owing to the extensive local invasion, a second surgery in August 2024 required a left nephrectomy, splenectomy, hemicolectomy, and distal pancreatectomy. The tumor's proximity to the abdominal aorta and invasion into the psoas muscle posed significant surgical challenges, requiring careful resection.
conclusionThis case highlights the aggressive nature of high-grade dedifferentiated liposarcoma and its resistance to chemotherapy. Surgical resection remains the primary treatment option, but the recurrence emphasizes the need for more effective therapies. The case further illustrates the complexity of multiorgan involvement in recurrent dedifferentiated liposarcoma and the critical role of experienced oncologic surgeons in managing these cases. More research is necessary to develop alternative treatments that can better control tumor progression and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.